Pagenax Solution for Injection

Introduction

Pagenax is a prescription medication that contains the active ingredient Brolucizumab. It is also available under the brand name Pagenax. This medication is primarily used for the treatment of certain eye conditions.

Uses

Pagenax is prescribed to treat neovascular (wet) age-related macular degeneration (AMD) in adults. Neovascular AMD is a condition that causes abnormal blood vessels to grow and leak in the back of the eye, leading to vision loss.

Dosage and Administration

Pagenax is administered as an injection into the eye by a healthcare professional. The recommended dosage is 6 milligrams (mg) per injection, which is equivalent to 0.05 milliliters (mL) of the solution. The injection is usually given once every 12 weeks for the first three doses, and then once every 8 to 12 weeks thereafter.

Mechanism of Action

Brolucizumab, the active ingredient in Pagenax, works by inhibiting a protein called vascular endothelial growth factor (VEGF). By blocking VEGF, the medication helps to reduce the growth of abnormal blood vessels in the eye and prevent leakage, thus slowing down the progression of neovascular AMD.

Side Effects

Common side effects of Pagenax may include eye pain, blurred vision, conjunctival hemorrhage (bleeding in the eye), and floaters. These side effects are usually mild and temporary. However, if you experience any persistent or severe side effects, contact your healthcare provider.

Serious side effects are rare but can occur. These may include infections in the eye, increased eye pressure, retinal detachment, and inflammation of the eye. If you experience any signs of a serious side effect, such as severe eye pain, sudden vision changes, or redness/swelling in the eye, seek immediate medical attention.

Drug Interactions

There are currently no known drug interactions with Pagenax. However, it is always important to inform your healthcare provider about all medications you are taking, including over-the-counter drugs and supplements, to ensure there are no potential interactions.

Precautions

Before using Pagenax, inform your healthcare provider about any allergies you may have, as well as your medical history, especially if you have a history of eye infections or inflammation. This medication should not be used if you have an active eye infection or certain other eye conditions.

Note that Pagenax may increase the risk of inflammation or infection in the eye. Your healthcare provider will monitor your eye health regularly while you are using this medication.

Storage

Pagenax should be stored in the refrigerator between 2°C and 8°C (36°F and 46°F). Do not freeze the medication. Keep it in the original carton to protect it from light. Once opened, the solution should be used within 28 days.

Patient Tips

• Follow the dosage schedule recommended by your healthcare provider. Do not miss any appointments for injections.
• If you are experiencing any discomfort or have any concerns after using Pagenax, contact your healthcare provider.
• Keep all follow-up appointments with your eye specialist to monitor the effectiveness of the medication and detect any potential side effects.
• Do not attempt to administer the medication yourself. It should only be administered by a healthcare professional trained in the proper technique.
• Store the medication as directed and check the expiration date before use.
• If you have any questions or concerns about Pagenax, speak with your healthcare provider for further information and guidance.

Please note that this description, as well as the other content on our website is for educational purposes only. We do not provide medical advice. For specific medical advices, diagnoses and treatment options you should consult with your doctor.

References

• Brolucizumab ophthalmic (Drugs.com) [Accessed 9 Jun. 2024] (online) Available at:
• brolucizumab-dbll 6 mg/0.05 ml intravitreal solution for injection (RX) [Accessed 21 Jun. 2024] (online) Available at:
• Brolucizumab-dbll Injection (MedlinePlus) [Accessed 8 Jun. 2024] (online) Available at:
• [No authors listed] Brolucizumab. 2023 Nov 15. Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. [Accessed 27 Jun. 2024] Available at: